Previous close | 1.8300 |
Open | 1.8300 |
Bid | 1.7200 x 400 |
Ask | 1.7500 x 600 |
Day's range | 1.6300 - 1.8611 |
52-week range | 1.5000 - 8.3300 |
Volume | |
Avg. volume | 1,912,624 |
Market cap | 155.424M |
Beta (5Y monthly) | 2.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations in B-NHL -- -- CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 -- -- CB-012 AMpLify Phase 1 trial advancing in dose escalation -- BERKELEY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR ge
BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, New York, NYSeptember 4, 2024 2024 Wells Fargo Healthcare Conference, Boston, MASeptember 5, 2024 During these conferences, Caribou leadership will conduct one-on-one meeting
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular thera